Cannabis Indica

Novacyt S.A.
Company typeSociété Anonyme
LSENCYT
EuronextALNOV
IndustryBiotechnology
Founded2006
HeadquartersCamberley, Surrey, United Kingdom
Key people
David Allmond (CEO)
ProductsIn vitro and molecular diagnostics
Subsidiaries
Websitewww.novacyt.com

Novacyt Group (/ˈnvəst/ NOH-və-syte) is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France.[1][2] The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide.[3] Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.[4]

In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV.[5][6][7][8] The test was approved as eligible for procurement under the World Health Organization's (WHO) Emergency Use Listing process in April 2020,[9] meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response.[10] In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory.[11][12]

References[edit]

External links[edit]


Leave a Reply